Anthony M Joshua

39PUBLICATIONS
337CO-AUTHORS
Predictive and prognostic markersPharmacogenomicsEpigenetics (incl. genome methylation and epigenomics)Cancer therapy (excl. chemotherapy and radiation therapy)Radiation therapy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (39)

|Jun 26, 2026
AI-Based Pathology classifier Predicts Sensitivity to Enzalutamide in Metastatic Hormone-Sensitive Prostate Cancer: A Biomarker Analysis of the ENZAMET Trial.

|Apr 28, 2026
177Lu-PSMA-617 SPECT/CT for Early Prediction of Overall Survival in Participants with Metastatic Castration-Resistant Prostate Cancer.

|Apr 15, 2026
Predictive value of early PSMA upregulation for the response to enzalutamide ± 177Lu-PSMA-617 in poor-risk, metastatic, castration-resistant prostate cancer: substudy of the randomized, phase 2 ENZA-p trial.

|Mar 27, 2026
Challenging interpretation of low-level PTCH1 mosaicism in patients with clinically diagnosed Gorlin syndrome: a case series and review of the literature.

Tanya M Dwarte, Rozanna Alli, Shweta Srinivasa

|Mar 25, 2026
Single-Cell and Spatial Transcriptomic Profiling Reveals Epithelial Functional States and Fibroblast Phenotypes in Hormone Therapy-Naïve Localized Prostate Cancer.

Eva Apostolov, Daniel L Roden, Holly Holliday

|Mar 06, 2026
A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.

Barak Talmor, Stefano Marastoni, Brandon Lau

Pageof 7

Frequent Collaborators

7 joint publications

Ian D Davis

7 joint publications

Martin R Stockler

4 joint publications

Hui-Ming Lin

4 joint publications

Louise Emmett